San Diego, CA, September 01, 2015 --(PR.com
)-- Epitope Diagnostics is proud to add Neutrophil Gelatinase-associated Lipocalin (NGAL) ELISA kit to its growing fecal test panel. This world-first ELISA kit (Cat. no. KT-853) quantitatively measures the amount of NGAL, also known as lipocalin-2 (LCN2), in human fecal specimen. Fecal NGAL is an excellent biomarker for the clinical diagnosis of inflammatory bowel disease (IBD).
While the clinical relevance of plasma NGAL is thoroughly understood and applied, the clinical applications of fecal NGAL is lesser known. Epitope Diagnostics has done extensive study and identified that fecal NGAL is actually a surprisingly stable biological marker. Many markers in fecal specimen are usually unstable due to degradation of structure and function by the multitude of enzymes and bacteria in the gut, yet NGAL has been found to be stable in stool for several days. This allows plenty of time for sample collection, transportation, and measurement in a clinical laboratory setting. Recent publications have further indicated fecal NGAL as an excellent marker for IBD.
The Epitope Diagnostics Fecal NGAL ELISA kit utilizes the sandwich assay technique and is extremely sensitive. In normal population, fecal NGAL concentration is less than 25 ug per gram of stool; in IBD patients, fecal NGAL concentration can be over 10,000 µg/g. This ELISA kit offers an analytical sensitivity (LLOD) of ~0.04 µg/g and does not exhibit a high-dose hook effect up to 64,800 µg/g.
Additionally, Epitope Diagnostics offers the Fecal NGAL Sample Collection Kit (Cat. no. KT-884) to paired with the Fecal NGAL ELISA Kit. This sample collection comes prefilled with buffer and provides a simple, clean sample collection process and storage.